Formulation innovation: Partnerships usher in next wave of solid dosage forms

Formulation innovation: Partnerships usher in next wave of solid dosage forms

Brought to you by Aenova

Overview

Active pharmaceutical ingredients, or APIs, are what make a drug a drug - they produce the desired effect. The process of formulation converts APIs into drug products that patients can use. Most marketed pharmaceutical drugs are manufactured in solid forms such as tablets, capsules, and powders. Now the long-standing, well standardized practice of formulation is facing new challenges. Some advanced APIs are not compatible with standard approaches to formulation due to issues with stability, solubility, or other physicochemical characteristics. In this whitepaper, you will learn about innovative new approaches to solid dosage formulation and how partnering with a contract development and manufacturing organization, or CDMO, that specializes in these techniques will benefit your drug development pipeline.

Key Objectives:

Understand the importance of solid dosage formulation
Learn how novel approaches to solid dosage formulation can improve bioavailability
Learn how innovative delivery systems can expand the utility of solid dosage forms
Understand what to look for in a CDMO formulation partner

Brought to you by:

Please complete the form to download the white paper.

Forwarded this link? Clear the form

Email Address*

Salutation*

First Name*

Last Name*

Company*

Job Title

Address 1*

City*

State*

Zip / Post Code*

Country*

Business Phone*

I would like to receive more information on products and services from the American Chemical Society

*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) and its sponsor via email. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy .